JPMorgan Equity Premium Income ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Equity Premium Income ETF trades at $57.87, while GeneDx Holdings Corp trades at $81.32 (market cap $2.44B). The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| JEPI | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.88 | $167.51 |
52-Week Low | $55.29 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $57.84, up 0.35% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent dividends of $0.39 and $0.37 highlight its income focus, while news coverage emphasizes its role in retirement portfolios amid competitive yield pressures from peers like SPYI and JEPQ.
The outlook is mixed: strong income appeal supports demand, but underperformance versus covered-call peers and tax inefficiencies risk long-term returns. Investors face trade-offs between monthly distributions and capital appreciation, with sentiment divided on whether JEPI's strategy justifies opportunity costs.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Trailing returns across standard periods
Latest headlines on both assets
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →